Clinical Trial Update: Intranasal Insulin in Frontotemporal Dementia (FTD) [Phase 2]

View source ↗

Summary

Phase 2 trial of intranasal insulin for frontotemporal dementia (behavioral variant) was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behavioral Variant Frontotemporal Dementia
• Frontotemporal Dementia

Drugs mentioned

• Intranasal insulin (insulin)

Snippet

Sponsor: HealthPartners Institute | Conditions: Frontotemporal Dementia, Behavioral Variant | Phase 2 | Status: TERMINATED | Results posted: 2023-07-06